Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
The Ireland-based company, according to Green Market Report, filed its 2023 patent-enforcement lawsuit against a dozen alleged infringers, including:
- Alkem Laboratories
- API Pharma Tech
- Apotex
- Ascent Pharmaceuticals
- Biophore Pharma
- InvaGen Pharmaceuticals and its parent, Cipla USA
- Lupin
- MSN Pharmaceuticals
- Padagis US
- Taro Pharmaceutical Industries
- Teva Pharmaceuticals.
- Zanara Pharma Private
One by one, the defendants reached settlements with Jazz, with Apotex being the last to settle, according to Green Market Report.
In 2021, Jazz acquired United Kingdom-based GW Pharmaceuticals – the developer of Epidiolex and one of the world’s largest medical cannabinoid businesses – for $7.2 billion, a record deal in the space.
Epidiolex has been approved in certain countries for the treatment of seizure disorders, including Canada, which approved the clinically tested drug in 2023 as an “adjunctive therapy” for certain rare and severe forms of epilepsy.
Epidiolex is considered the top-selling cannabinoid-based medicine in the world.
In the nine months ending in September 2024, the drug generated $697.3 million in revenue, up 15.2% from the same period a year earlier, according to Jazz’s third-quarter financials.
The company’s shares are traded as JAZZ on the Nasdaq stock exchange.
Bruce Cozadd, who oversaw Jazz’s acquisition of Epidiolex as co-founder, chair and CEO, plans to retire in late 2025 after a successor is appointed.
Medical Disclaimer:
The information provided in these blog posts is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The use of any information provided in these blog posts is solely at your own risk. The authors and the website do not recommend or endorse any specific products, treatments, or procedures mentioned. Reliance on any information in these blog posts is solely at your own discretion.
